Abirami Sivapiragasam
Expertise in
11
conditions

Dr. Abirami Sivapiragasam

Hematology Oncology | Oncology
86 Jonathan Lucas St, 2nd Floor, 3rd Floor, 
Charleston, SC 
Accepting New Patients
Offers Telehealth
Expertise in
11
conditions
86 Jonathan Lucas St, 2nd Floor, 3rd Floor, 
Charleston, SC 

Overview

Dr. Abirami Sivapiragasam is a board-certified hematologist and oncologist with over a decade of experience. Currently, she is the Director of Medical Oncology at the MUSC Hollings Cancer Center and an Associate Professor of Medicine at the Medical University of South Carolina. Previously, she worked as an Associate Professor of Medicine at the SUNY Upstate Medical University Hospital in Syracuse, NY. During her tenure there, she also served as the Program Director for the Hematology and Oncology Fellowship program.Dr. Sivapiragasam is an expert in the diagnosis and treatment of breast cancer. She is also a skilled educator, having trained medical students, residents, and fellows.As a member of the American Society of Clinical Oncology and the American Board of Internal Medicine, Dr. Sivapiragasam is committed to keeping up with the latest advancements in her field. Additionally, she is a published researcher in her area of expertise.Dr. Sivapiragasam is known for her compassionate and dedicated approach to patient care. She is a respected leader in the field of breast oncology and is highly regarded in the medical community.

Dr. Sivapiragasam is highly rated in 11 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Angiosarcoma, Laryngeal Cancer, Paget Disease of the Breast, and Bone Marrow Aspiration.

She is actively involved in clinical research, co-authoring 25 peer reviewed articles and participating in 7 clinical trials. Dr. Sivapiragasam is currently accepting new patients.

Specialties

Hematology Oncology
Oncology

Licenses

Internal Medicine in NY

Fellowships

NYU-Langone Hospital, Long Island, 2015

Hospital Affiliations

Musc Medical Center

Languages Spoken

English
Russian

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Absolute Total Care South Carolina
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

MUSC Health Hematology Oncology at Hollings Cancer Center
86 Jonathan Lucas St, 2nd Floor, 3rd Floor, Charleston, SC 29425

Additional Areas of Focus

Dr. Sivapiragasam has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma
Breast Cancer

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2026
Intervention Type: Procedure, Biological, Drug, Radiation
Study Drugs: Docetaxel, Nab-Paclitaxel, Paclitaxel, Pertuzumab, Trastuzumab, Trastuzumab Emtansine
Study Phase: Phase 2
The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared With T-DM1 and Tucatinib
The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared With T-DM1 and Tucatinib
Enrollment Status: Active_not_recruiting
Publish Date: June 15, 2026
Intervention Type: Other, Biological, Drug
Study Drugs: Trastuzumab Emtansine, Tucatinib
Study Phase: Phase 3
ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
Enrollment Status: Active_not_recruiting
Publish Date: June 05, 2026
Intervention Type: Drug
Study Drugs: Fulvestrant, Anastrozole
Study Phase: Phase 3
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Enrollment Status: Terminated
Publish Date: May 29, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Atezolizumab, Paclitaxel, Pertuzumab, Trastuzumab
Study Phase: Phase 3
View 6 Less Clinical Trials

25 Total Publications

Tumour-infiltrating lymphocytes and breast radiotherapy: perspectives from the International Immuno-Oncology Biomarker Working Group.
Tumour-infiltrating lymphocytes and breast radiotherapy: perspectives from the International Immuno-Oncology Biomarker Working Group.
Journal: The Lancet. Oncology
Published: January 11, 2026
Similar Doctors
Expertise in
17
conditions
Dr. Thai H. Ho
Hematology Oncology | Oncology
Expertise in
17
conditions
Dr. Thai H. Ho
Hematology Oncology | Oncology
Referral may be required

MUSC Health Hematology Oncology At Hollings Cancer Center

86 Jonathan Lucas St, 2nd Floor, 3rd Floor, 
Charleston, SC 
 (0.1 miles away)
843-792-9300
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Thai Ho has been caring for patients affected by genitourinary cancers for over 10 years. His area of expertise and the focus of his research is in treating kidney and bladder cancers. He also sees patients with kidney, bladder, upper tract urothelial, and prostate cancers, as well as patients affected by hereditary cancer syndromes. Dr. Ho completed the Baylor College of Medicine Physician Scientist Program in 2006, internal medicine residency at Washington University in St. Louis in 2009, and Medical Oncology Fellowship at MD Anderson Cancer Center in 2012.Dr. Ho's research is funded by the National Institutes of Health and Department of Defense to better match cancer patients with targeted therapies by using precision medicine approaches to identify a cancer's unique vulnerabilities. At MUSC Hollings Cancer Center, Dr. Ho is the Director of Precision Medicine and an Associate Professor in the Division of Hematology \& Oncology. Prior to joining MUSC, Dr. Ho was an Associate Professor faculty the Mayo Clinic where he was a member of the Center for Individualized Medicine Epigenomics Group, Genomic Tumor Board, and von Hippel-Lindau Clinic. Dr. Ho is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Clear Cell Sarcoma, WT1-Related Wilms Tumor Syndromes, Nephrectomy, and Orchiectomy. Dr. Ho is currently accepting new patients.

Expertise in
36
conditions
Expertise in
36
conditions
Referral may be required

MUSC University Hospital

171 Ashley Ave, 
Charleston, SC 
 (0.2 miles away)
843-792-2300
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Scott Lindhorst is an Oncologist practicing medicine in Charleston, South Carolina. Dr. Lindhorst is highly rated in 36 conditions, according to our data. His clinical expertise encompasses Astrocytoma, Glioblastoma, Glioma, Brain Tumor, and Awake Craniotomy. Dr. Lindhorst is currently accepting new patients.

Expertise in
37
conditions
Dr. Robert K. Stuart
Hematology | Oncology
Expertise in
37
conditions
Dr. Robert K. Stuart
Hematology | Oncology
Referral may be required

MUSC University Hospital

171 Ashley Ave, 
Charleston, SC 
 (0.2 miles away)
843-792-1414
Languages Spoken:
English
See accepted insurances

Robert Stuart is a Hematologist and an Oncologist practicing medicine in Charleston, South Carolina. Dr. Stuart is highly rated in 37 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Multiple Myeloma, Bone Marrow Aspiration, and Bone Marrow Transplant.

Frequently Asked Questions about Dr. Abirami Sivapiragasam

How do I make an appointment with Dr. Abirami Sivapiragasam?

You can book an appointment with Dr. Abirami Sivapiragasam by calling their office at 843-792-9300. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Abirami Sivapiragasam a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Abirami Sivapiragasam is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Abirami Sivapiragasam specialize in?

While Dr. Abirami Sivapiragasam is a Hematology Oncology, they have specific expertise in Breast Cancer, Angiosarcoma, and Laryngeal Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology Oncology.

Does Dr. Abirami Sivapiragasam participate in research or clinical trials?

Yes. Dr. Abirami Sivapiragasam has published 25 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Abirami Sivapiragasam's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Abirami Sivapiragasam accept my insurance?

Dr. Abirami Sivapiragasam accepts most major insurance plans, including Absolute Total Care South Carolina and Aetna. We recommend calling the office directly at 843-792-9300 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sivapiragasam's expertise for a condition
ConditionClose
    View All 64 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile